ORAL VINORELBINE PLUS CISPLATIN VERSUS PEMETREXED PLUS CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A COST MINIMIZATION ANALYSIS IN TWELVE EUROPEAN COUNTRIES

被引：0
|
作者：
Bucher, D. [1 ]
Grossi, F. [2 ]
机构：
[1] Pierre Fabre, Boulogne Billancourt, France
[2] Natl Inst Canc Res, Genoa, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1112
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN96
引用
收藏
页码：A446 / A446
页数：1
相关论文
共 50 条
  • [31] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Pu Xiaolin
    Wang Jun
    Li Wei
    Lu Binbin
    Wang Zhaoxia
    Yang Min
    Fan Weifei
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209
  • [32] An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer
    Nuijten, Mark J. C.
    Aultman, Rick
    de Castro Carpeno, Javier
    Vergnenegre, Alain
    Chouaid, Christos
    Walzer, Stefan
    Siebert, Uwe
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) : 2193 - 2201
  • [33] Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer
    Scaqliotti, G.
    Park, K.
    Patil, S.
    Rolski, J.
    Gorksel, T.
    Gans, S. J. M.
    Martins, R.
    Visseren-Grul, C.
    Peterson, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 363 - 363
  • [34] S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan
    Lai, Chun-Liang
    Wei, Yu-Fen
    Hsia, Te-Chun
    Chang, Gee-Chen
    Wu, Jiun-Ting
    Chen, Jung-Yueh
    Chen, Yuh-Min
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (02) : E68 - E73
  • [35] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China
    Liu, Huiqin
    Wang, Ying
    He, Qi
    HEALTH ECONOMICS REVIEW, 2022, 12 (01)
  • [36] CLINICAL EFFICACY OF VINORELBINE PLUS CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER
    童茂荣
    夏锡荣
    曹鄂洪
    施毅
    赵蓓蕾
    Chinese Journal of Cancer Research, 1996, (03) : 74 - 76
  • [37] Cisplatin plus vinorelbine chemotherapy for non-small cell lung cancer
    Pereira, JR
    Gampel, O
    Martins, SJ
    Ikari, FK
    Nikaedo, SM
    Paschoalini, M
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 643 - 646
  • [38] Oral vinorelbine (NVBo) plus cisplatin (CDDP) versus pemetrexed (PEM) plus CDDP followed by maintenance with single agent NVBo or PEM as first-line treatment of patients (pts) with advanced non-squamous non small cell lung cancer (NS-NSCLC): A cost minimization analysis from the Italian National Health System (NHS) perspective
    Favaretto, A.
    Ciuffreda, L.
    Nicolini, M.
    Camerini, A.
    Melotti, B.
    Berardi, R.
    Mencoboni, M.
    Lucioni, C.
    Mazzi, S.
    Bennouna, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S329 - S329
  • [39] Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer
    Montalar, J
    Morales, S
    Maestu, I
    Camps, C
    Vadell, C
    García, R
    Yuste, AL
    Torregrosa, D
    Segura, A
    LUNG CANCER, 2001, 34 (02) : 305 - 311
  • [40] PEMETREXED PLUS PLATINE IN FIRST LINE FOR TREATMENT OF ADVANCED AND METASTATIC NON-SQUAMOUS CELL LUNG CANCER
    Mehenni, Nawel
    Bensaou, Malika Gamaz
    Bouzid, Kamel
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1164 - S1164
12345